. 2023 Jan 12;13(1):14. doi: 10.1038/s41408-022-00768-5

Table 1.

Cytogenetic risk subgroups by study and treatment group.

	Evaluable for del(17p), t(4;14), and t(14;16) cytogenetic abnormalities N = 2247				Evaluable for del(17p), t(4;14), t(14;16), and amp1q21 cytogenetic abnormalities N = 2098
Patients, n (%)	Ixazomib-based (n = 1228)		Placebo-based (n = 1019)		Ixazomib-based (n = 1143)		Placebo-based (n = 955)
	High risk	Standard risk^a	High risk	Standard risk^a	Expanded high risk	Standard risk^a	Expanded high risk	Standard risk^a
TOURMALINE-MM1	75	200	62	216	155	122	154	126
TOURMALINE-MM2	60	231	63	234	134	164	146	153
TOURMALINE-MM3	61	252	54	152	116	154	88	89
TOURMALINE-MM4	74	275	48	190	150	148	91	108
Total	270 (22)	958 (78)	227 (22)	792 (78)	555 (49)	588 (51)	479 (50)	476 (50)

^aStandard risk complement of (expanded) high risk (i.e., patients without any of the specified abnormalities).